Investigators are now interested in assessing potential benefits of direct-acting antivirals for HCV patients who previously had liver cancer.
New study results show that, despite recent international clinical analysis, direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) is not associated with a greater recurrence of liver cancer in patients who have suffered from both conditions.
According to research from the University of Texas Southwestern Medical Center, rates of cancer aggressiveness and recurrence in DAA-treated patients with hepatitis C was no different from those not given antiviral therapy. The findings come as a benefit to patients and physicians alike; DAAs have been evidenced to provide a near-perfect rate of hepatitis C eradication in patients, with virus life cycle-targeting mechanism and proven tolerability.
Lead by Amit G. Singal, MD, MS, an associate professor of Internal Medicine and medical director of the Liver Tumor Program, investigators informed their analysis based on the findings of a 2016 study in Spain, which suggested that a greater rate of liver cancer recurrence could be associated with the antiviral treatment of patients with hepatitis C.
But the team also pointed to the study’s small cohort size, its lacking untreated control arm, and its short median duration of follow-up—from their perspective, the study’s makeup “limited any definitive conclusions about harms related to HCV therapy, including which patients were at highest risk for early recurrence.”
To improve on previous efforts, investigators conducted a retrospective cohort analysis of patients with HCV-related hepatocellular carcinoma (HCC) that had been previously treated from 2013-2017 at 31 different US- or Canada-based health systems. Qualified patients had previously reported a complete response to resection, local ablation, trans-arterial chemo- or radioembolization, or radiation therapy.
In the 793 patients identified with HCV-associated HCC, 304 (38.3%) were treated with DAAs, and the rest (489; 61.7%) were untreated. The team used a Cox regression analysis to assess the association between DAA therapy and patients’ time to recurrence after a complete response. DAAs were treated as a time-varying exposure.
Their analysis showed that HCC recurred in less than half of DAA-treated patients (128; 42.1%), with an early recurrence being reported in 52 of those patients. Among patients not treated with DAAs, the HCC recurrence was greater (288; 58.9%), with early recurrence reported in a majority of patients (227).
After adjusting for various factors, investigators concluded that hazard ratio of DAA therapy was not great enough to associate the drug class with neither HCC recurrence (0.90; 95% CI: 0.70-1.16) nor early recurrence (0.96; 95% CI: 0.70-1.34).
|Read on: Hepatitis C Therapy Not Linked to Liver Cancer Recurrence|